98%
921
2 minutes
20
Conventional titanium (Ti)-based implants often fail to achieve osseointegration in bone defects accompanied by rheumatoid arthritis (RA), primarily due to the RA pathological microenvironment, characterized by elevated reactive oxygen species (ROS) levels and hypoxia. This microenvironment induces mitochondria dysfunction and intracellular Ca overload, facilitating macrophage polarization toward the M1 phenotype and thus impairing osteoimmunomodulatory osseointegration. To address this challenge, a nanozyme-inspired coating, featuring the deposition of MnFeO nanoparticles onto a polydopamine (PDA)-decorated surface of microporous TiO, is constructed on Ti (known as MFO coating). The osteoimmunomodulatory osseointegration of the coating, both in vitro and in vivo, accompanied by RA was assessed, and the underlying mechanisms were also investigated. Due to the efficient conversion of HO into O and robust ROS-scavenging capabilities, the coating mitigates mitochondria ROS accumulation and intracellular Ca overload induced by the pathological microenvironment, while simultaneously elevating intracellular O levels, thereby preventing macrophage apoptosis. Meanwhile, by improving the microenvironment, the coating activates moderate mitophagy through the Ca-AMPK-mTOR signaling pathway, facilitating the removal of dysfunctional mitochondria and the preservation of mitochondrial dynamics and integrity. As a result, the restored mitochondria reprogram their metabolic pathway from relying on anaerobic to relying on aerobic oxidative phosphorylation, facilitating macrophage polarization toward the M2 phenotype, which not only inhibits osteoclastogenesis but also accelerates osseointegration in rats with RA. The coating presents a transformative approach to Ti-based implant design for bone defects associated with inflammatory diseases, potentially reducing the risk of revision surgery and offering a long-lasting lifespan for patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsnano.5c07535 | DOI Listing |
Cell Physiol Biochem
September 2025
Department of General Practice, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China, E-Mail:
Background/aims: Ubiquitin D (UBD), a member of the ubiquitin-like modifier (UBL) family, is significantly overexpressed in various cancers and is positively correlated with tumor progression. However, the role and underlying mechanisms of UBD in rheumatoid arthritis (RA) remain poorly understood. This study aimed to investigate the effects of UBD knockdown on the progression of RA.
View Article and Find Full Text PDFClin Exp Immunol
September 2025
Rheumatology Department, Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (APHP), CEA , FHU CARE, Le Kremlin Bicêtre, France.
Introduction: Immunosenescence remodels immune functions and was first described with aging. It is present in 25% of cancer patients but has also been described in patients with Immune-mediated inflammatory diseases (IMIDs). This study aims at quantifying cells exhibiting a phenotype of senescence in CD4+ (T4sen) and CD8+ (T8sen) T cells, analyzing its potential drivers and the effect of anti-TNF treatment in a prospective cohort of patients with rheumatoid arthritis (RA), spondyloarthritis (SpA) and Sjögren disease (SjD).
View Article and Find Full Text PDFKorean J Intern Med
September 2025
Hanyang University Institute for Rheumatology Research, Seoul, Korea.
Background/aims: To identify factors associated with achieving low disease activity (LDA) after 48 weeks of targeted therapy in patients with rheumatoid arthritis (RA) despite not meeting treat-to-target (T2T) criteria at week 24.
Methods: Data were collected from a multicenter, prospective observational cohort of Korea patients with RA receiving targeted therapy between April 2020 and July 2023. Patients who continued their initial targeted therapy despite not achieving LDA at week 24 were assigned to the LDA and non-LDA groups at week 48.
Int J Biol Macromol
September 2025
School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, 211166, PR China; State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine (Tianjin Institute of Pharmaceutical Research), Tianjin, PR China. Electronic address:
Rheumatoid arthritis (RA) is an autoimmune disease typically characterized by joint pain and dysfunction. Ammopiptanthus nanus (M. Pop.
View Article and Find Full Text PDFEur J Pharm Biopharm
September 2025
Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, PR China. Electronic address:
Iguratimod (IGU) is a novel anti-rheumatic drug, which has anti-inflammatory effects, inhibits bone destruction, and promotes bone formation. However, the gastrointestinal side-effects caused by oral tablets of IGU pose a challenge. This study aimed to develop an IGU transdermal patch for Rheumatoid Arthritis (RA) through ion-pair and chemical penetrant strategies to improve the therapeutic efficacy.
View Article and Find Full Text PDF